A Retrospective NIS to Evaluate the Use of Seroquel XR and IR in the Clinical Practice of Outpatients With Schizophrenia
Completed
- Conditions
- Schizophrenia
- Registration Number
- NCT01212575
- Lead Sponsor
- AstraZeneca
- Brief Summary
The primary objective of this non-interventional study is to investigate how Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia. This will be done by a retrospective review of medical records to evaluate patients treated with Seroquel XR or Seroquel IR as primary antipsychotic treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 186
Inclusion Criteria
- Adults with a diagnosis of schizophrenia from a district psychiatric clinic in Denmark
- Patients who have received at least one dose of Seroquel XR or Seroquel IR during January - March 2010
Exclusion Criteria
- Patients already participating in a clinical study during the study-period.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method How Seroquel XR and Seroquel IR are used in the clinical practice of outpatients with schizophrenia Month 3
- Secondary Outcome Measures
Name Time Method Co-morbidities of patients with schizophrenia receiving Seroquel XR and IR Month 3 Whether Seroquel XR and Seroquel IR are used to treat different types of outpatients with schizophrenia by evaluation of patient characteristics Month 3 The treatment sequence of Seroquel XR and Seroquel IR in the clinical practice of patients with schizophrenia by evaluation of duration, dosage, reason for treatment, and, if applicable, reason for change, with Seroquel XR and Seroquel IR Month 3
Trial Locations
- Locations (1)
Research Site
🇩🇰Tonder, Denmark